HHS Announces Initial Vaccine Candidates and More Than $500M in Awards for Project NextGen

The U.S. Department of Health and Human Services (HHS), last week, through the Administration for Strategic Preparedness and Response (ASPR), announced the selection of initial next-generation vaccine candidates and more than $500 million in awards for Project NextGen to advance innovative next-generation vaccine and therapeutics platforms.

The awards announced today will support companies as they prepare their vaccine candidates for Phase 2b clinical evaluation: $8.5 million to CastleVax for a vector-based intranasal vaccine candidate; $10 million to Codagenix for a live-attenuated intranasal vaccine candidate; and $10 million to Gritstone Bio for a self-amplifying mRNA vaccine candidate. Read more from HHS here.